Comment to “Deep vein thrombosis induced by vasculitis in the Behçet’s syndrome”
Behçet’s syndrome (BS) is a rare, complex autoimmune disorder that can inflame blood vessels, skin, joints, eyes, and even the gastrointestinal tract. When it causes deep vein thrombosis (DVT)—a blood clot in the leg—treatment becomes a high-stakes balancing act: too little care, and inflammation-driven clots worsen; too much, and bleeding risks skyrocket. A 2018 case report of a 37-year-old man with BS and DVT has shed light on critical gaps in how we manage these patients—and why following updated guidelines could mean the difference between recovery and tragedy.
The case, published by Chen Y and Guan JL in the Chinese Medical Journal, describes a man with a 5-year BS history who developed DVT in his leg. After stopping warfarin (a blood thinner) for 7 days to prepare for a GI endoscopy, he developed severe upper abdominal pain. A CT scan found only small kidney stones, but the next morning he suffered chest pain, shortness of breath, and cardiac arrest—dying despite an hour of resuscitation.
Ya-Nan Guo, Shi Tai, Liang Tang, and Sheng-Hua Zhou—cardiologists from the Second Xiangya Hospital of Central South University in Changsha, China—recently commented on this case in the Chinese Medical Journal (2019). Their analysis raises three urgent questions about BS care that every clinician and patient should understand:
1. Anticoagulation in BS-Related DVT: Clot Risk vs. Bleeding Dangers
BS-related DVT isn’t like typical DVT. Instead of being caused by “thick blood” (hypercoagulability), it stems from vasculitis—inflammation in the vein walls. A meta-analysis of three studies found that adding anticoagulants to immunosuppressive drugs didn’t lower DVT recurrence rates. But the 2018 update to the EULAR (European League Against Rheumatism) guidelines for BS management offers a key rule: anticoagulants should only be used if arterial aneurysms are ruled out. Why? Nearly all BS patients with aneurysms (bulges in artery walls) have a history of DVT—and anticoagulants can turn a stable aneurysm into a life-threatening bleed.
In the case, the patient never underwent tests to check for arterial aneurysms (like a pulmonary artery aneurysm). The authors suspect his death may have been from a ruptured aneurysm—not a pulmonary embolism (a clot in the lungs). Even more concerning: stopping warfarin for an endoscopy was risky. For patients with refractory venous thrombosis (clots that won’t resolve), guidelines advise against pausing anticoagulants without a strong reason.
2. Immunosuppression: The Core of BS Care—And When to Escalate
The golden rule for BS-related DVT? Immunosuppressants are non-negotiable. Research shows these drugs (which calm the overactive immune system) reduce DVT recurrence far better than anticoagulants alone. The 2018 EULAR guidelines recommend combining glucocorticoids (e.g., prednisone) with medications like azathioprine, cyclophosphamide, or cyclosporine A for acute DVT. For patients with refractory DVT (clots that don’t improve with first-line treatment), monoclonal anti-TNF antibodies (a biologic therapy) are a promising option—they’ve helped BS patients with hard-to-treat arterial disease.
The case patient initially responded to immunosuppressive therapy, but his symptoms worsened suddenly on day 7 of hospitalization. This, the authors note, signals that first-line treatments weren’t enough. Guidelines suggest switching to anti-TNF antibodies—but here’s the catch: no studies have compared which immunosuppressant works best. More clinical trials are needed to answer this question.
3. Gastrointestinal Involvement in BS: Why Indomethacin Isn’t the Answer
BS often targets the GI tract, causing gastrointestinal Behçet’s syndrome (GIBS). This complication most commonly affects the colon and ileocecal region (where the small and large intestines meet). It’s rare but dangerous: 3–60% of BS patients develop GIBS, and nearly a third need emergency surgery for perforation or massive bleeding.
The case patient was given indomethacin (a pain reliever) rectally for his abdominal pain. But the authors argue this was a mistake. For GIBS, guidelines recommend glucocorticoids to heal ulcers, plus 5-aminosalicylate (5-ASA) or azathioprine to prevent relapse. If symptoms don’t improve, emergency surgery is critical—delaying can be fatal. The authors also caution that Budd-Chiari syndrome (a liver vein blockage) can mimic GIBS symptoms and must be ruled out.
The Big Takeaway for BS Patients
BS is often misdiagnosed because its early symptoms (mouth ulcers, skin rashes) are vague. But when it progresses to DVT, GI involvement, or aneurysms, it becomes life-threatening. The case highlights three key lessons:
- Exclude aneurysms before using anticoagulants—bleeding risks are too high.
- Immunosuppressants are the foundation of DVT care—don’t rely on anticoagulants alone.
- GI symptoms in BS need urgent, guideline-aligned care—indomethacin isn’t a fix for inflammation-driven ulcers.
The authors—affiliated with the Department of Cardiology at the Second Xiangya Hospital of Central South University—stress that BS requires a multidisciplinary approach (cardiologists, rheumatologists, gastroenterologists) to spot complications early. And because BS is rare, prospective clinical trials are essential to fill gaps in our knowledge.
The original case report was published by Chen Y and Guan JL in the Chinese Medical Journal (2018). The comment by Guo et al. was published in the Chinese Medical Journal (2019).
doi.org/10.1097/CM9.0000000000000120
Was this helpful?
0 / 0